Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague
Oral presentation gives more details from the Phase II data where topline results were released on June 29, 2023. Investigators for the Phase II trial concluded that: · The majority of the glioma patients displayed uPAR-positive tumors · High uPAR expression is significantly correlated with a worse outcome · The study demonstrates the potential of uPAR-targeted radionuclide therapy (uTREAT®) for patients with high-grade gliomas Copenhagen, Denmark, September 14, 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that the previously announced